产品图片
货号/SKU
NR-46417
货号/规格
EA
库存与交货期
3-8周
人民币价格
14000
试剂海关审批
A/B级风险物质只能直接使用人购买并持有实验室有效资质，其它询客服确认
国外采购
支持/部分限制一年内购买数量
厂牌
BEI Resources(ATCC)
产品基础信息
生物安全等级建议分类：美国、2
产品描述信息
NR-46417??Staphylococcus aureus, AIS 2006045(Bacteria)|Staphylococcus aureus|AIS 2006045|-60°C or colder|J PatelAcknowledgment for publications should read "The following reagent was provided by the Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA) for distribution by BEI Resources, NIAID, NIH: Staphylococcus aureus, Strain AIS 2006045, NR-46417."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
Staphylococcus aureus (S. aureus), strain AIS 2006045 (also referred to as VRSA-7, VRS7) was isolated in 2006 in Michigan, USA from a triceps wound of a 43-year-old female with necrotizing fasciitis of the right upper limb who had been recently treated with a five-week course of vancomycin.
S. aureus, strain AIS 2006045 is a vancomycin-resistant S. aureus (VRSA) strain and is reported to be resistant to a number of other antimicrobial agents. S. aureus, strain AIS 2006045 was deposited as positive for mec (subtype II) and vanA; negative for vanB, vanC1, vanC2, vanD, vanE, PVL and arginine catabolic mobile element (ACME); pulsed-field type USA100; spa repeats TJMBMDMGMK; Ridom spa type t002. S. aureus, strain AIS 2006045 is a USA100 isolate. USA100 isolates have the same MLST profile (ST 5) and SCCmec (subtype II) and are usually resistant to β-lactams, erythromycin and spectinomycin as well as being multiresistant to other commonly used therapeutic agents. USA100 is the most prevalent U.S health care-associated pulsed-field type and is endemic in many U.S. hospitals. S. aureus, strain AIS 2006045 is partially dependent on vancomycin for growth due to a mutation in D-alanyl:D-alanine ligase (Ddl), an enzyme involved in biosynthesis of peptidoglycans. The presence of the vanA operon compensates for the Ddl mutation by providing alternative peptidoglycans for cell wall synthesis; however, some have found that this change in the type of peptidoglycans produced renders it susceptible to oxacillin. The complete genome sequence of S. aureus, strain AIS 2006045 is available (GenBank: AHBQ00000000).
Each vial contains approximately 0.5 mL of bacterial culture in Brain Heart Infusion broth supplemented with 6 ?g/mL vancomycin and 10% glycerol.
Staphylococcus aureus (S. aureus), strain AIS 2006045 (also referred to as VRSA-7, VRS7) was isolated in 2006 in Michigan, USA from a triceps wound of a 43-year-old female with necrotizing fasciitis of the right upper limb who had been recently treated with a five-week course of vancomycin.
S. aureus, strain AIS 2006045 is a vancomycin-resistant S. aureus (VRSA) strain and is reported to be resistant to a number of other antimicrobial agents. S. aureus, strain AIS 2006045 was deposited as positive for mec (subtype II) and vanA; negative for vanB, vanC1, vanC2, vanD, vanE, PVL and arginine catabolic mobile element (ACME); pulsed-field type USA100; spa repeats TJMBMDMGMK; Ridom spa type t002. S. aureus, strain AIS 2006045 is a USA100 isolate. USA100 isolates have the same MLST profile (ST 5) and SCCmec (subtype II) and are usually resistant to β-lactams, erythromycin and spectinomycin as well as being multiresistant to other commonly used therapeutic agents. USA100 is the most prevalent U.S health care-associated pulsed-field type and is endemic in many U.S. hospitals. S. aureus, strain AIS 2006045 is partially dependent on vancomycin for growth due to a mutation in D-alanyl:D-alanine ligase (Ddl), an enzyme involved in biosynthesis of peptidoglycans. The presence of the vanA operon compensates for the Ddl mutation by providing alternative peptidoglycans for cell wall synthesis; however, some have found that this change in the type of peptidoglycans produced renders it susceptible to oxacillin. The complete genome sequence of S. aureus, strain AIS 2006045 is available (GenBank: AHBQ00000000).
Each vial contains approximately 0.5 mL of bacterial culture in Brain Heart Infusion broth supplemented with 6 ?g/mL vancomycin and 10% glycerol.
主要内容
此项目的每个订单数量限制为1.此项目每年可订购两次.在此限制之前的订单将被发送到发货前的批准. 葡萄球菌金黄色葡萄球菌（S. aureus），菌株AIS 2006045（也称为VRSA-7 ，VRS7）于2006年在密歇根州分离，来自一只43岁女性的伤口伤口，右上肢的坏死性筋膜炎，最近患有五周的万古霉素课程. s.金黄色葡萄球菌，菌株AIS 2006045是一种万古霉素抗性. AUREUS （VRSA）菌株，并据报道耐什么抗微生物剂. s.金黄色葡萄球菌，菌株AIS 2006045沉积为 MEC（亚型II）和 vana ; Vanb ， Vanc1， Vanc2 ， vand ， vane ，pv1和精氨酸分解代谢移动元素（ACME）;脉冲场型USA100; spa 重复tjmbmdmgmk; ridom spa 型T002. s. AUREUS ，菌株AIS 2006045是USA100隔离物. USA100分离株具有相同的MLST谱（ST 5）和SCC MEC （亚型II），并且通常耐β-内酰胺，红霉素和北霉素以及多霉素，以及多敏感剂与其他常用的治疗剂. USA100是最普遍的美国医疗保健相关的脉冲场类型，在许多美国医院的地方是流行的. s. AUSUS ，菌株AIS 2006045部分依赖于由于D-丙氨酸：D-丙氨酸连接酶（DDL）的突变，其参与肽聚糖的生物合成的酶导致的vancomycin.通过提供用于细胞壁合成的替代肽聚糖来补偿DDL突变的 vana 的存在;然而，有些人发现这种肽聚糖类型的这种变化产生的蛋白质易患牛奶蛋白. s的完整基因组序列. aureus ，应变AIS 2006045可用（Genbank： ahbq00000000 ）. 每个小瓶在脑心脏输注肉汤中含有大约0.5毫升的细菌培养，其补充有6μg/ ml万古霉素和10％甘油.
厂牌介绍
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立，旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中，可以监控科学界对这些材料的访问和使用，并确保试剂的质量控制。
除了为传染病界提供材料外，BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势，包括安全存储、社区访问和分发；同时保护存款人的知识产权。只要有需要，BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月， ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料，包括由其他政府支持的研究项目存放的材料，将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中，涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
品牌标识
可能感兴趣的内容
2021-12-21
2022-04-01
2021-12-02
2023-07-18
2024-05-19
2022-04-01
2021-12-21
2021-12-02
2023-12-18
2024-05-19
2024-08-16
2022-04-01
2022-04-01
2022-04-01
2022-03-31
2022-04-01
2024-07-31
2024-01-21